期刊文献+

儿童神经母细胞瘤临床诊疗的研究进展 被引量:12

Progress in Clinical Diagnosis and Treatment of Children with Neuroblastoma
下载PDF
导出
摘要 神经母细胞瘤是婴儿、孩童时期常见的颅外实体肿瘤疾病,具有异质性高、生物学行为复杂、分子特征多样等特点,不同患儿发病后的临床差异较大,疾病可自行痊愈、自然退化或迅速发展。近年来,随着临床对儿童神经母细胞瘤研究的不断深入,儿童神经母细胞瘤的诊断与治疗已经进入到新的分子生物学时代,儿童神经母细胞瘤的早期筛查、准确诊断及合理治疗等诸多相关方面均有不同的进展,相较于既往的诊断与治疗经验均有优化。目前诊断儿童神经母细胞瘤的方法包括常规诊断、基因分子生物学诊断、基因检测等,而治疗常采用化疗、放疗、免疫治疗及造血干细胞移植等,各具优缺点。 Neuroblastoma is a common extracranial solid tumor disease in infants and children. It has the characteristics of high heterogeneity,complex biological behaviors and diverse molecular features. The clinical differences in different children after onset are large,and the disease may heal itself,naturally degenerate or develop rapidly. In recent years,with the deepening of the clinical research,the diagnosis and treatment have entered a new era of molecular biology. Early screening,accurate diagnosis and reasonable treatment have all made developments,which are optimized compared with previous diagnostic and therapeutic experiences. At present,the main diagnostic methods include routine diagnosis,gene molecular biological diagnosis,gene detection,etc.,and the common treatment methods include chemotherapy,radiotherapy,immunotherapy and hematopoietic stem cell transplantation,each with own advantages and disadvantages.
作者 夏剑锋 张倩 梅海 XIA Jianfeng;ZHANG Qian;MEI Hai(Department of Pediatric Surgery,Guizhou Province Tumor Hospital,Guiyang 550000,China)
出处 《医学综述》 2020年第4期690-694,共5页 Medical Recapitulate
关键词 神经母细胞瘤 分子生物学 基因 化疗 放疗 免疫治疗 Neuroblastoma Molecular biology Genes Chemotherapy Radiotherapy Immunotherapy
  • 相关文献

参考文献7

二级参考文献80

  • 1高晓宁,唐锁勤,林季.晚期儿童神经母细胞瘤的临床和预后分析[J].中国当代儿科杂志,2007,9(4):351-354. 被引量:7
  • 2Haupt R, Garaventa A, Gambini C, et al. Improved survival of children with neurohlastoma between 1997 and 2005 : A report of the halian neuroblastoma registry. Clin Oncol, 2010, 28 : 2331-2338.
  • 3Pandey GK, Kandul'i C. Long noncoding RNAs and neuroblastoma. Oncotarget, 2015,6 : 18265-18275.
  • 4Castel V, Grau E, Noguera R, et al. Molecular biology of neuroblastoma. Clin transl oncol, 2007, 9 : 478-483.
  • 5Buechner J, Einvik C. N-myc and noncoding RNAs in neuroblastoma. Mol Cancer Res, 2012, 10 : 1243-1253.
  • 6Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INGR) classification system: an INGR Task Force report. J Clin Oncol, 2009, 27:289-297.
  • 7Rich BS, McEvoy MP, Kelly NE,et al. Resectahility and operative morbidity after chemotherapy in neuroblastoma patients with encasement of major visceral. J Pediatr Surg, 2011, 46 : 103-107.
  • 8Moon SB, Park KW, Jung SE, et al. Neuroblastoma: treatment outcome after incomplete resection of primary tumors. Pdeiatr Surg Int, 2009, 25: 789-793.
  • 9Warmann SW, Seitz G, Schaefer JF, et al. Vascular encasement as element of risk stratification in abdominal neuroblastoma. Surg Oncol, 2011, 20:231-235.
  • 10DuBosi SG, Chesler L, Groshen S, et al. Phase I study of Vincristine, irinotecan, and Imetaiodobenzylguanidine for patients with relapsed or refractory neuroblastoma: A new approaches to neuroblastoma therapy trial. Clin Cancer Res, 2012, 18: 2679-2686.

共引文献48

同被引文献87

引证文献12

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部